Genetic variations associated with low plasma adiponectin levels predispose to insulin resistance and CVD, and increased circulating adiponectin—by either genetic or pharmacological approaches—has been shown to ameliorate insulin sensitivity in the liver and the skeletal muscle, as well as glucose tolerance [3]. Here, ADIPOQ is linked to Insulin resistance.